Jun Yoon - 01 Mar 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Jun Yoon
Issuer symbol
GPCR
Transactions as of
01 Mar 2025
Net transactions value
-$95,489
Form type
4
Filing time
03 Jul 2025, 17:15:08 UTC
Previous filing
19 Mar 2024
Next filing
18 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yoon Jun CHIEF FINANCIAL OFFICER C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO /s/ Jun Yoon 03 Jul 2025 0001962414

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GPCR Ordinary Shares Tax liability $47,025 -5,940 -0.46% $7.92 1,287,359 01 Mar 2025 Direct F1, F2
transaction GPCR Ordinary Shares Award $0 +39,606 +3.1% $0.000000 1,326,965 01 Jul 2025 Direct F1, F3
transaction GPCR Ordinary Shares Tax liability $48,465 -7,089 -0.53% $6.84 1,319,876 01 Jul 2025 Direct F1, F2
holding GPCR Ordinary Shares 1,554,586 01 Mar 2025 See footnote F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GPCR American Depositary Shares Award $0 +831 +39% $0.000000 2,946 21 May 2025 Ordinary Shares 2,963 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
F2 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
F3 On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.
F4 By Jun Sik Yoon and Hayung Yang Yoon, Trustees of The Yoon Family Trust, dated December 11, 2019.
F5 Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.